---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-014359"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T20:57:23.806725+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma Q1 2025 net loss $10.3M; prepares LYMPHIR launch H1 2025

## Summary
- Net loss of $10.3M ($1.30 per share) vs. $9.2M ($1.45) in Q1 2024; cash $1.1M as of Dec 31, 2024.
- G&A expenses rose to $5.4M on pre-launch LYMPHIR activities; R&D fell to $2.1M as trials completed.
- LYMPHIR received permanent J-code (J9161) effective April 1, 2025; launch expected in first half 2025.
- Citius Oncology engaged Jefferies to evaluate strategic alternatives; raised $6.5M in equity placements.
- Nasdaq compliance regained after 1-for-25 reverse stock split in November 2024.

## SEC filing metadata
- accession: 0001213900-25-014359
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390025014359/0001213900-25-014359-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390025014359/ea0231245-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-014359
- JSON: https://secwatch.observer/filing/0001213900-25-014359.json
- Plain text: https://secwatch.observer/filing/0001213900-25-014359.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.